SCHEDULE: Millennium Entities Disclose 5.2% Stake in iBio, Inc.

Integrated Core Strategies, Millennium Management, Millennium Group Management, and Israel A. Englander have jointly reported a 5.2% beneficial ownership stake in iBio, Inc. common stock.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G, indicating their beneficial ownership in iBio, Inc.
• Integrated Core Strategies (US) LLC beneficially owns 1,234,295 shares of iBio, Inc. Common Stock.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially own 1,235,827 shares of iBio, Inc. Common Stock.
• The aggregate beneficial ownership for each reporting person represents 5.2% of iBio, Inc.'s outstanding Common Stock.
• This percentage is calculated based on 23,895,789 shares of Common Stock outstanding, which includes 22,487,308 shares as of November 10, 2025, and an additional 1,408,481 shares issued in a private placement around January 13, 2026.
• The reporting persons share both voting and dispositive power over the reported securities.
• The securities were acquired and are held not for the purpose of changing or influencing the control of iBio, Inc.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of a significant beneficial ownership stake by a prominent institutional investor group. While neutral in its direct content, the establishment of a 5.2% stake by such entities can be interpreted as a moderately positive signal for the issuer, iBio, Inc., suggesting institutional interest and potential confidence.

Positives

• A prominent institutional investor group, including Millennium Management, has established a significant 5.2% stake in iBio, Inc., which could signal confidence in the company's future prospects.

Negatives

• No specific negative information regarding iBio, Inc.'s operations or financial performance is disclosed in this beneficial ownership report.

Risks

• This filing is a disclosure of beneficial ownership and does not contain specific risk factors related to iBio, Inc.'s business or financial condition.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in iBio, Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name and common stock structure. Such an investment by a prominent hedge fund group like Millennium Management can be seen as a vote of confidence in the company's potential within its industry, though the filing itself does not provide details on iBio's specific business activities or broader industry trends.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake could increase investor confidence and potentially influence trading activity.
• Company (iBio, Inc.): The presence of a major institutional investor on its shareholder register could provide stability or signal external validation.

Key Dates

Keywords

iBio Inc, IBIO, Millennium Management, Integrated Core Strategies, Israel A. Englander, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology